Introduction
As of 19 May 2024, the global number of coronavirus disease 2019 (COVID-19) cases had reached 775 million, with a total reported mortality of about 7 million worldwide [1]. In Hong Kong, the study site, more than 3 million people were infected with SARS-CoV-2 with a cumulative death of 9,287 recorded [2,3]. Albeit people may fully recover from the infection, some people may be prone to the sequelae of COVID-19 by experiencing long COVID symptoms [Reference Chen4].
Long COVID, or post-COVID-19 condition that proposed by the World Health Organization (WHO), occurs in people with history of SARS-CoV-2 infection, which the symptoms continue or develop three months after the onset of SARS-CoV-2 infection and last for at least two months that cannot be explained by other diagnosis [5]. However, there was a lack of consensus in defining long COVID conditions in studies conducted prior to the issuance of WHO definition, which created challenges to estimate the overall prevalence of such conditions. A meta-analysis estimated the global pooled prevalence of post-COVID-19 conditions, which was defined as having any symptoms or at least one new or persisting symptom at least 28 days after infection [Reference Chen4]. The results showed that the global pooled prevalence of post-COVID-19 conditions was about 50% for hospitalized and 34% for non-hospitalized COVID-19 survivors [Reference Chen4]. However, such prevalence might be overestimated as asymptomatic individuals were not reflected in most included studies of the aforementioned meta-analysis. Moreover, included studies conducted in early 2020 mainly focussed on older and higher-risk individuals and might not reflect the situation in general population [Reference Chen4]. In Hong Kong, 55% of patients reported having any long COVID symptom after infection with the Omicron variant in a study adhered to the WHO definition, which the study investigated the prevalence of long COVID among non-hospitalized patients with confirmed SARS-CoV-2 infection that received consultation services provided by a Chinese medicine research institute [Reference Luo6]. Some people who contracted SARS-CoV-2 may be prone to experience multiple long COVID symptoms for more than six months [Reference Xie, Bowe and Al-Aly7], the multi-manifestations of symptoms across organs led this condition to also be coined as post-COVID syndrome [Reference Mantovani8]. Fatigue, cognitive symptoms (e.g., brain fog), breathlessness or dyspnoea, muscle pain or myalgia, and sleep problems were the most common long COVID symptoms observed across review studies [Reference Chen4,Reference Michelen9]. Long COVID symptoms may induce detrimental or even devastating effects to daily functioning and employment [Reference Nehme10], mental health [Reference Righi11], perceived physical health [Reference Nehme10,Reference Righi11], and health-related quality of life [Reference Michelen9]. Furthermore, studies showed that long COVID was associated with a substantial increase in utilization of healthcare services (both inpatient and outpatient) and economic costs [Reference Tene12].
Previous studies have identified some factors associated with the development of long COVID symptoms. A positive association between severity of SARS-CoV-2 infection during the acute phase and long COVID was observed [Reference Kayaaslan13]. Patients with more than five symptoms during the initial SARS-CoV-2 infection and those that required hospital admission were more likely to develop long COVID [Reference Sudre14]. Pre-existence of certain chronic health conditions, such as asthma, diabetes, heart disease, and neurocognitive and mental health conditions at the onset of SARS-CoV-2 infection were also significantly associated with long COVID [Reference Sudre14,Reference Taquet15]. Additionally, some demographic characteristics were associated with long COVID. For example, studies showed that females and older age were found to be more likely to exhibit long COVID [Reference Chen4]. These factors were examined in the current study.
COVID-19 vaccination is one of the most cost-effective measures to prevent infection, deaths, and other severe consequences caused by COVID-19 [Reference Rotshild16,Reference Beladiya17]. Two underlying mechanisms have been suggested for the association between taking up COVID-19 vaccination booster doses and reduced odds of long COVID. First, as booster doses are effective in reducing the severity of COVID-19 infection, this may then translate into a lower risk of developing organ or systemic derangements, and thus reduce symptoms onset and duration which consequently result in lower odds of long COVID [Reference Notarte18]. Second, booster doses may accelerate clearance of the remaining SARS-CoV-2 in the human body or could also reduce the exaggerated inflammatory and/or immune response associated with long COVID development [Reference Notarte18,Reference Marshall19]. In Hong Kong, two types of COVID-19 vaccines are available, i.e., the inactivated and mRNA vaccines [20]. A systematic review identified 12 studies reporting the associations between vaccination status before SARS-CoV-2 infection and the presence of any long COVID symptoms [Reference Byambasuren21]. These studies focussed on the effects of mRNA (Pfizer or Moderna) or viral vector vaccines (Janssen or AstraZeneca) [Reference Byambasuren21]. The odds ratio (OR) of developing long COVID with one dose of vaccine ranged from 0.22 to 1.03, and 0.25 to 1.00 with two doses [Reference Byambasuren21]. Only one study reported that three doses of mRNA COVID-19 vaccines could significantly reduce the risk of long COVID (OR: 0.16) [Reference Byambasuren21]. Another study reported that taking up two doses of any COVID-19 vaccines, including mRNA, viral vector, and inactivated vaccines, was associated with lower odds of any long COVID [Reference Romero-Ibarguengoitia22]. However, the aforementioned study did not specify the protective effects conferred by different types of COVID-19 vaccines [Reference Romero-Ibarguengoitia22]. To our knowledge, there was a lack of studies investigating the protective effects of three doses of inactivated COVID-19 vaccines on long COVID. Moreover, no study compared the effectiveness of three doses of mRNA vaccines with three doses of inactivated vaccines in reducing the odds of long COVID.
To address the aforementioned knowledge gaps, this study aimed at examining the associations between three doses of COVID-19 vaccination (mRNA and inactivated vaccine) and (1) having any of the long COVID symptoms and (2) ≥3 types of long COVID symptoms among people with a history of SARS-CoV-2 infection in Hong Kong, China.
Methods
Study design
This study is a secondary analysis of a cross-sectional online survey investigating the associations between sedentary lifestyles and the risk of acute and post-acute COVID-19 sequelae among residents in Hong Kong between June and August 2022 [Reference Zheng23]. The fifth wave of the outbreak of COVID-19 that dominated by the Omicron variant occurred between December 2021 and April 2022 in Hong Kong. The original study was launched approximately three months after the peak of the wave. We extracted a sub-sample of participants who self-reported having confirmed SARS-CoV-2 infection during the fifth wave of the COVID-19 outbreak from the original study for current investigation.
Participants and data collection
Inclusion criteria of the original online survey were (1) adults aged 18 years or above, (2) currently living in Hong Kong, (3) able to read traditional Chinese or English, and (4) with internet access. The original online survey, which consist of 243 questions in Chinese and English that took about 20 mins to complete, was developed by using Qualtrics with the advertisement and survey link distributed through social media, websites, e-mails, online groups, posters, and leaflets. In the advertisement of the original online survey, the aim towards investigating the associations between sedentary lifestyles and symptoms or sequelae of COVID-19 during the fifth wave of COVID-19 in Hong Kong was delineated, and people could participate in the survey regardless of contracting with SARS-CoV-2 or not. Before starting the online survey, participants read a statement that participation was voluntary and their personal information would be kept confidential. Digital informed consent was obtained before participants could start answering the online survey. The online survey platform checked for completeness before submission, allowing participants to review and change their responses. No incentives were given to participants. The data were stored on the survey platform server and protected by password. Only the principal investigator of this project had the access to the database. During the study period, a total of 7,089 people accessed the original online survey, 87 did not provide consent to join the study, 60 were ineligible (not living in Hong Kong or under 18 years old), 2092 did not complete the survey, and 4,850 completed the online survey. We extracted a sub-sample of 1,542 participants, who self-reported having confirmed SARS-CoV-2 infection (either by nucleic acid amplification tests [NAAT] or rapid antigen testing [RAT]) during the fifth wave of outbreak (between December 2021 and April 2022) for the analysis. The original study was conducted in accordance with the principles of Declaration of Helsinki and approved by the Survey and Behavioural Research Ethics Committee, The Chinese University of Hong Kong (SBRE-21-0762).
Measures
Sociodemographic characteristics (age, sex assigned at birth, ethnicity, relationship status, personal monthly income, education level, employment status, and living alone or not) and health conditions and lifestyles (e.g. body mass index, current smoking and drinking status, presence of chronic health conditions, history of organ transplantation) were collected. Participants also reported hospital admission and intensive care unit admission due to SARS-CoV-2 infection during the fifth wave of COVID-19 outbreak in Hong Kong.
Self-reported long COVID symptoms were measured with reference to the definition proposed by the WHO [5]. First, participants were asked “Did you experience the following symptoms after SARS-CoV-2 infection or during the period between March and June 2022? If you experienced such symptoms before SARS-CoV-2 infection, please select no”. Participants were asked to indicate from a checklist of 14 common post-COVID-19 conditions, which included: (1) fatigue, (2) shortness of breath, (3) chest pain or tightness, (4) problems with memory and concentration (brain fog), (5) difficulty to fall asleep, (6) heart palpitations, (7) dizziness, (8) pins and needles, (9) joint pain, (10) feeling depressed or anxious, (11) persistent cough, (12) muscle pain, (13) loss of smell or taste, and (14) fever with response categories of 1 = Yes and 2 = No. Following each of the aforementioned symptoms, a question on tapping the duration of the symptom (1 = less than one week, 2 = 1 week to less than 1 month, 3 = 1 to 2 months, 4 = more than 2 months) was asked. Participants who experienced any of these symptoms for more than 2 months after SARS-CoV-2 infection or during the period between March and June 2022 were considered exhibiting long COVID. Owing to the multi-manifestation nature of long COVID symptoms across organs, the presence of ≥3 types of long COVID symptoms was also measured apart from exhibiting any of the 14 common long COVID symptoms.
COVID-19 vaccination status was measured by a number of doses and types of COVID-19 vaccines received prior to the fifth wave of the COVID-19 outbreak. In Hong Kong, an inactivated COVID-19 vaccine (SinoVac CronaVac) and mRNA vaccine (Pfizer-BioNTech) were available. During the time when this study was conducted, adults in Hong Kong were required to present vaccination records before entering public spaces. The vaccination pass contained information about number of doses, vaccine type, and date of COVID-19 vaccines received by the users.
Information related to SARS-CoV-2 infection was also collected. Participants were asked if they were infected with SARS-CoV-2 for the first time during the fifth wave of the COVID-19 outbreak in Hong Kong (1 = yes, 2 = no, 3 = unknown) and methods for confirming infection (NAAT, RAT, or both). The overall severity of SARS-CoV-2 infection was gauged by asking them to rate the severity with the response categories: 1 = asymptomatic (no symptoms), 2 = mild (with common symptoms, but without shortness of breath, dyspnoea, or abnormal chest imaging), 3 = moderate (with shortness of breath or severe cough), 4 = severe (with dyspnoea or abnormal chest imaging), and 5 = critical (with respiratory failure, septic shock, or multiple organ dysfunctions).
Statistical analysis
Descriptive statistics towards frequencies and percentages were used to present all study variables. Using having any self-reported long COVID symptoms and self-reported ≥3 types of long COVID symptoms as the dependent variables, univariate logistic regression models were employed to measure the associations between outcome variables and sociodemographic characteristics, health conditions and lifestyles, and SARS-CoV-2 infection with OR and respective 95% confidence interval (CI) reported. Then, a single multivariate logistic regression model was fitted involving COVID-19 vaccination status and all significant variables related to sociodemographic characteristics, health conditions and lifestyles, and SARS-CoV-2 infection for obtaining the adjusted odds ratio (AOR) with 95% CI reported. In addition, multivariate logistic regression models were conducted to compare the effects of three doses of inactivated vaccines with three doses of mRNA vaccines (reference group) in reducing the odds of any self-reported long COVID symptoms and self-reported ≥3 types of long COVID symptoms, after adjusting for all significant variables related to sociodemographic characteristics, health conditions and lifestyles, and COVID-19 infection. All analyses were conducted using SPSS (version 28; IBM Corp., Armonk, NY, USA) with P < 0.05 considered as statistically significant.
Results
Sociodemographic characteristics, health conditions and lifestyles, and SARS-CoV-2 infection
Approximately half of the participants were aged 18–30 years (51.3%) and had a normal range of BMI (18.5–22.9) (52.0%). About two-thirds were females (63.2%), currently single (68.5%), and had a personal monthly income higher than HK $13400 (US $1717.9) (65.4%). The majority were Chinese (99.4%), full-time employed (82.4%), not current smokers (95.1%), not binge drinkers (95.5%), attained tertiary education or above (79.2%), living with other household member (92.0%), and without a history of organ transplantation (99.9%). Less than 10% had any of the chronic conditions (8.4%).
The date of receiving confirmed SARS-CoV-2 infection during the fifth wave of the COVID-19 outbreak was between 3 January 2022 and 29 April 2022. Only 14 (0.9%) participants were hospitalized, and none of them were admitted to the ICU due to SARS-CoV-2 infection. The majority of participants were infected with SARS-CoV-2 for the first time (97.9%) and had mild symptoms (76.2%). Approximately half of them used RAT to confirm SARS-CoV-2 infection (56.7%). (Table 1).
Background characteristics of the participants (n = 1,542)
Self-reported long COVID symptoms
The prevalence of any long COVID symptoms and ≥ 3 types of long COVID symptoms was 40.9% and 16.1% respectively. The most commonly reported long COVID-19 symptoms were brain fog (25.9%), followed by fatigue (20.4%), difficulty to fall asleep (11.3%), and feeling depressed or anxious (8.5%). (Table 1).
COVID-19 vaccination status
Among the participants, 1,379 (89.4%) of them received at least two doses of COVID-19 vaccination. Among 491 (31.8% of all respondents) participants who received at least three doses of COVID-19 vaccination, the most common choice was three doses of Pfizer-BioNTech (n = 345), followed by three doses of SinoVac CoronaVac (n = 98), two doses of SinoVac CoronaVac plus one dose of Pfizer-BioNTech (n = 32), and two doses of Pfizer-BioNTech plus one dose of SinoVac CoronaVac (n = 11) (Table 1 and Table S1 in Appendix 1).
Factors associated with self-reported having any long COVID symptoms
Older age (31–40 years: OR: 1.61, 95% CI: 1.24, 2.08, P < .001; 41–50 years: OR: 1.92, 95% CI: 1.41, 2.62, P < .001; reference: 18–31 years), being female (OR: 1.35, 95% CI: 1.10, 1.68, P = .01), and having moderate-to-severe symptoms following SARS-CoV-2 infection (OR: 3.54, 95% CI: 2.00, 6.28, P < .001; reference: asymptomatic) were associated with higher odds of having any long COVID-19 symptoms (Table 2). After adjusting for these significant variables, receiving at least three doses of COVID-19 vaccination was associated with lower odds of having any long COVID symptoms (AOR: 0.69, 95% CI: 0.54, 0.87, P = .002; reference group: receiving 2 doses). (Table 3).
Associations between background characteristics and self-reported long COVID symptoms
OR: crude odds ratios.
CI: confidence interval.
Associations of COVID-19 vaccination status and COVID-19 infection with self-reported long COVID symptoms (n = 1,542)
AOR: adjusted odds ratios, odds ratios adjusted for significant variables related to sociodemographic characteristics, health conditions and lifestyles, and COVID-19 infection during the fifth wave of COVID-19 outbreak in Hong Kong listed in Table 2
CI: confidence interval.
Factors associated with self-reported having ≥ 3 types of long COVID symptoms
As compared to participants who were 18–30 years, those aged 31–40 years (OR: 2.00, 95% CI: 1.43, 2.81, P < .001) and 41–50 years (OR: 2.55, 95% CI: 1.74, 3.74, P < .001) had higher odds of reporting multiple long COVID symptoms. In addition, being female (OR: 1.49, 95% CI: 1.11, 2.00, P = .01), married with a partner (OR: 1.34, 95% CI: 1.01, 1.78, P = .04), had a personal monthly income of HK $13400–29,500 (US $1717–3,782.1) (OR: 1.60, 95% CI: 1.16, 2.22, P = .004; reference group: < HK $13400), and had moderate-to-severe symptoms following SARS-CoV-2 infection (OR: 3.13, 95% CI: 1.44, 6.82, P < .001; reference: asymptomatic) were also associated with higher odds of reporting ≥3 types of long COVID symptoms (Table 2). After adjusting for these significant variables, the association between receiving at least three doses of COVID-19 vaccination and having ≥3 types of long COVID symptoms was not statistically significant (AOR: 0.72, 95% CI: 0.51, 1.00, P = .051; reference group: receiving 2 doses). (Table 3).
Associations between types of COVID-19 vaccination received by the participants and self-reported long COVID symptoms
As compared to those who received two doses of Pfizer-BioNTech, participants who received three doses of Pfizer-BioNTech or SinoVac CoronaVac had lower odds of reporting any long COVID-19 symptoms (three doses of Pfizer-BioNTech: AOR: 0.68, 95% CI: 0.52, 0.90, P = .006; three doses of SinoVac CoronaVac: AOR: 0.57, 95% CI: 0.35, 0.90, P = .02) (Table S2 in Appendix 1). As compared to those who received three doses of Pfizer-BioNTech, participants who received three doses of SinoVac CoronaVac had similar odds of reporting any long COVID symptoms (AOR: 0.74, 95% CI: 0.44, 1.23, P = .25) or ≥ 3 types of long COVID symptoms (AOR: 0.82, 95% CI: 0.40, 1.68; P = .59).
Discussion
This study contributed evidence to the associations between receiving three doses of inactivated COVID-19 vaccines and presence of any and ≥ 3 long COVID symptoms among Chinese people with SARS-CoV-2 infection during the Omicron predominance. This was also one of the first studies to compare the protective effects of three doses of inactivated vaccines and three doses of mRNA vaccines on reducing odds of long COVID symptoms. The findings provided some useful data about how different combinations of primary and booster COVID-19 vaccine doses would affect likelihood of long COVID symptoms. Such findings might have implications on vaccination programme planning in China and other countries that mainly used inactivated and mRNA COVID-19 vaccines.
In this study, 40.9% of participants self-reported having any long COVID symptoms. Such level was lower than the figures observed in mainland China (45–76%) [Reference Shang24–Reference Huang27] and the pooled prevalence in Asia (51%) [Reference Chen4]. One possible reason for the difference might be the age distributions between study samples. Our participants were younger (26.3% were over 40 years old) than studies conducted in mainland China (78.3% were over 40 years) [Reference Shang24,Reference Xiong25] and other Asian countries such as India (72% were over 40 years) [Reference Areekal28]. Increasing age was consistently shown to be associated with a higher risk of experiencing long COVID [Reference Chen4]. Hong Kong is an ageing society, and the proportion of individuals aged 65 years or above reached 20.5% in 2021 [29]. The risk of SARS-CoV-2 infection was higher among older adults as compared to their younger counterparts during the fifth wave of COVID-19 outbreak in Hong Kong [Reference Cheung, Chan and Jin30]. Therefore, our findings could only reflect the situations among younger adults in Hong Kong. Future studies are needed to understand the levels of long COVID symptoms among older adults.
Our findings also highlighted the role of COVID-19 vaccination booster dose in reducing risk of long COVID symptoms. As compared to participants that completed their primary series of COVID-19 vaccination (receiving 2 doses), receiving at least three doses of COVID-19 vaccine were associated with lower odds of reporting any long COVID symptoms. Such findings were consistent with those observed by previous studies [Reference Azzolini31,Reference Di Fusco32]. Our study suggested that receiving three doses of mRNA (Pfizer-BioNTech) and inactivated (SinoVac CoronaVac) vaccines, the most common choices of COVID-19 vaccines in Hong Kong, were both associated with significantly lower odds of reporting any long COVID symptoms. Moreover, the protective effects conferred by three doses of mRNA vaccines and three doses of inactivated vaccines were similar in reducing odds of long COVID symptoms. These findings supported the growing research that using mRNA COVID-19 vaccine as a booster dose had a protective effect against long COVID symptoms [Reference Azzolini31] and added new evidence that using inactivated vaccines could also reduce the odds of long COVID symptoms. Therefore, it is important to strengthen the coverage of COVID-19 vaccination booster doses, even in the post-pandemic era. Previous systematic review and meta-analysis revealed that heterologous vaccination (the combination of inactivated-mRNA vaccines) had the highest antibody responses, and it was more effective than homologous vaccination [Reference Cheng33]. However, we were not able to observe similar associations in this study due to the relatively small number of participants with heterologous vaccination.
In line with previous studies, older age and female gender were associated with higher odds of having self-reported long COVID symptoms [Reference Huang27,Reference Bai34,Reference Mohamed, Moulin and Schiöth35]. Increased age was associated with a decline in organ functions and a slower ability to recover from acute SARS-CoV-2 infection [Reference Huang27]. Previous studies suggested that hormones might play a role in perpetuating the hyper-inflammatory status of the acute phase after recovery [Reference Mohamed, Moulin and Schiöth35,Reference Bienvenu36]. As compared to males, females produced stronger IgG antibodies in the early phase of COVID-19, which might also play a role in perpetuating disease manifestations [Reference Mohamed, Moulin and Schiöth35,Reference Bienvenu36]. In addition, females are likely to be more attentive to their body than males [Reference Bai34]. As compared to asymptomatic infection, participants reported having moderate or severe symptoms of acute SARS-CoV-2 infection had higher odds of reporting long COVID symptoms. Previous studies suggested that in acute infection, the levels of cGAS, STING, and IFN-α were higher in patients with severe symptoms than those with mild or no symptoms [Reference Queiroz37]. Long COVID symptoms were associated with elevated cGAS, STING, and IFN-α levels [Reference Queiroz37]. Therefore, individuals affected by SARS-CoV-2 who are older, female gender, and having more severe symptoms should be identified and involved early in the follow-up programmes for long COVID management.
Nonetheless, this study had several limitations. First, it is possible that people without any long COVID symptoms were less likely to be interested in participating in the survey. Therefore, the prevalence of long COVID symptoms was likely to be overestimated by this study. Second, failure to measure the time since the last vaccination was another major limitation of this study. The protection conferred by primary and booster doses of COVID-19 vaccines were declining over time [Reference Patalon38]. Hong Kong started to offer a third dose of COVID-19 vaccine as booster on 11 November 2021 [39]. The fifth wave of COVID-19 outbreak in Hong Kong occurred between December 2021 and April 2022. Therefore, the variance of time interval between the completion of booster dose and confirmed SARS-CoV-2 infection during the fifth wave might be relatively small (0–5 months) in this study. Third, as compared to the census data in Hong Kong, older adults were under-sampled by this study [29]. Our findings mainly reflected the situation of younger adults in Hong Kong. Fourth, the data were self-reported and recall bias might exist. Information about COVID-19 vaccination status and long COVID symptoms could not be verified. Fifth, we were not able to know the response rate of this study due to the sampling design. We could not collect information from those who have seen the study information but did not access the link of online survey. Characteristics between the refusals and participants might be different, selection bias existed. Moreover, the causal relationship between the COVID-19 vaccination status and presence of long COVID symptoms could not be established as this was a cross-sectional survey study.
Conclusions
Among people with a history of SARS-CoV-2 infection in Hong Kong, 40.9% and 16.1% self-reported having any and multiple (≥3 types) long COVID symptoms. Individuals affected by SARS-CoV-2 that are older, female gender, and having more severe symptoms should be identified and involved early in the follow-up programmes for long COVID management. Our findings also highlighted the role of COVID-19 vaccination booster dose in reducing the risk of long COVID symptoms. It is important to strengthen the coverage of COVID-19 vaccination booster doses, even in the post-pandemic era.
Supplementary material
The supplementary material for this article can be found at http://doi.org/10.1017/S0950268824001687.
Data availability statement
The data presented in this study are available from the corresponding author upon request. The data are not publicly available as they contain sensitive personal behaviours.
Acknowledgements
The authors would like to express their gratitude to all the participants for their engagement in this study.
Author contribution
Conceptualization: C.Z., F-y.Y., P.S.F.C., F.S., Z.W.; Methodology: C.Z., F-y-Y, P.S.F.C., F.S., Z.W.; Data curation: C.Z., F.S., X-K.C., W.Y-J.H, S.H-S.W, Y.F.; Formal analysis: F-y.Y., P.S.F.C., Z.W.; Project administration: C.Z., F.S., X-K.C., W.Y-J.H., S.H-S.W., Y.F.; Supervision: C.Z., F.S., W.Y-J.H, S.H-S.W., Z.W.; Writing-original draft preparation: C.Z., F-y.Y., P.S.F.C., F.S., Y.F., Z.W.; Writing-review and editing: C.Z., F-y.Y., P.S.F.C., F.S., X-K.C., W.Y-J.H., Y.F., Z.W. All authors have read and agreed to the published version of the manuscript.
Funding statement
This work was supported by the Research Grants Council (RGC) General Research Fund (GRF), Hong Kong [14608521]; and University Grants Committee, The Chinese University of Hong Kong, Hong Kong [3110155].
Competing interest
The authors declare that they have no competing interests.
Ethical standard
Ethics approval was obtained from the Survey and Behavioural Research Ethics Committee, The Chinese University of Hong Kong (SBRE-21-0762). Informed consent was obtained from all participants.
Open access
